Nitric oxide and glutamate are contributors of anti-seizure activity of rubidium chloride: A comparison with lithium.
Animals
Anticonvulsants
/ pharmacology
Chlorides
/ pharmacology
Glutamic Acid
/ metabolism
Lithium Chloride
/ pharmacology
Male
Mice
Neuroprotective Agents
/ pharmacology
Nitric Oxide
/ metabolism
Pentylenetetrazole
Receptors, N-Methyl-D-Aspartate
/ metabolism
Rubidium
/ pharmacology
Seizures
/ chemically induced
Signal Transduction
Lithium
Mice
NMDA receptor
Nitrergic pathway
Pentylenetetrazole
Rubidium
Journal
Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130
Informations de publication
Date de publication:
24 08 2019
24 08 2019
Historique:
received:
27
11
2018
revised:
19
06
2019
accepted:
22
06
2019
pubmed:
27
6
2019
medline:
6
2
2020
entrez:
26
6
2019
Statut:
ppublish
Résumé
The neuro-protective effects of rubidium and lithium as alkali metals have been reported for different central nervous system dysfunctions including mania and depression. The aim of this study was evaluating as well as comparing the effects of rubidium chloride (RbCl) and lithium chloride (LiCl) on different seizures paradigms in mice and determining the involvement of NMDA receptors and nitrergic pathway. To assess the seizures threshold, animals received intravenous pentylenetetrazole (PTZ, 0.5%; 1 mL/min). Male NMRI mice (6-8 weeks) received intraperitoneal (i.p.) injections of different doses of RbCl and LiCl. Doses greater than 10 mg/kg of RbCl showed a significant anticonvulsant activity 60 min after administration; the anticonvulsant effects of LiCl was observed at the doses more than 5 mg/kg and after 30 min in PTZ-induced seizure threshold. But, RbCl (10, 20 mg/kg, i.p) or LiCl (5, 10 mg/kg, i.p) injection did not induce protection against maximal electroshock (MES) or intraperitoneal injection of PTZ lethal dose (80 mg/kg)-induced seizure models. Pre-treatment with L-NAME (non-selective nitric oxide synthase (NOS) inhibitor, 10 mg/kg; i.p.) and 7-nitroindazole (selective neuronal NOS inhibitor, 30 mg/kg; i.p.) enhanced the anticonvulsive effects of both RbCl (5 mg/kg, i.p.) and LiCl (1 mg/kg, i.p.) in PTZ-induced seizure threshold model. Injection of MK-801 (NMDA receptor antagonist, 0.05 mg/kg; i.p.) before RbCl (5 mg/kg, i.p.; P < 0.001) and LiCl (1 mg/kg, i.p.; P < 0.001) administration increased the anti-seizure activity. But, treatment with L-arginine (precursor of nitric oxide, 100 mg/kg; i.p.) decreased the seizure threshold of both RbCl (20 mg/kg, i.p.; P < 0.001) and LiCl (10 mg/kg, i.p.; P < 0.001). Measurement of nitrite levels in hippocampus of animals revealed a remarkable reduction after treatment with RbCl (20 mg/kg, i.p; P < 0.05) and LiCl (10 mg/kg, i.p; P < 0.01). To conclude, rubidium may protect central nervous system against seizures in PTZ-induced seizures threshold model through NMDA/nitrergic pathways with a similarity to lithium effects in mice.
Identifiants
pubmed: 31238129
pii: S0304-3940(19)30452-5
doi: 10.1016/j.neulet.2019.134349
pii:
doi:
Substances chimiques
Anticonvulsants
0
Chlorides
0
Neuroprotective Agents
0
Receptors, N-Methyl-D-Aspartate
0
Nitric Oxide
31C4KY9ESH
Glutamic Acid
3KX376GY7L
Lithium Chloride
G4962QA067
Rubidium
MLT4718TJW
rubidium chloride
N3SHC5273S
Pentylenetetrazole
WM5Z385K7T
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
134349Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.